Financial Sense Advisors Inc. Boosts Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Financial Sense Advisors Inc. increased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 267,310 shares of the company’s stock after buying an additional 17,310 shares during the period. Teva Pharmaceutical Industries accounts for about 1.2% of Financial Sense Advisors Inc.’s investment portfolio, making the stock its 18th biggest position. Financial Sense Advisors Inc.’s holdings in Teva Pharmaceutical Industries were worth $3,772,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in TEVA. Desjardins Global Asset Management Inc. increased its stake in Teva Pharmaceutical Industries by 15.2% during the fourth quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company’s stock worth $85,000 after acquiring an additional 1,070 shares during the last quarter. DekaBank Deutsche Girozentrale increased its stake in Teva Pharmaceutical Industries by 2.1% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 67,996 shares of the company’s stock worth $688,000 after acquiring an additional 1,375 shares during the last quarter. Transcend Capital Advisors LLC increased its stake in Teva Pharmaceutical Industries by 13.6% during the fourth quarter. Transcend Capital Advisors LLC now owns 12,543 shares of the company’s stock worth $131,000 after acquiring an additional 1,500 shares during the last quarter. Nordea Investment Management AB increased its stake in Teva Pharmaceutical Industries by 1.7% during the fourth quarter. Nordea Investment Management AB now owns 89,136 shares of the company’s stock worth $931,000 after acquiring an additional 1,521 shares during the last quarter. Finally, Truist Financial Corp increased its stake in Teva Pharmaceutical Industries by 1.3% during the fourth quarter. Truist Financial Corp now owns 134,022 shares of the company’s stock worth $1,399,000 after acquiring an additional 1,766 shares during the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 519,000 shares of the company’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the completion of the sale, the director now owns 981,000 shares in the company, valued at $16,706,430. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, insider Vikki L. Conway sold 15,219 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $16.74, for a total transaction of $254,766.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Roberto Mignone sold 519,000 shares of the stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total value of $8,838,570.00. Following the sale, the director now owns 981,000 shares of the company’s stock, valued at approximately $16,706,430. The disclosure for this sale can be found here. Insiders sold a total of 549,719 shares of company stock worth $9,353,736 over the last 90 days. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 1.5 %

Shares of NYSE TEVA opened at $16.80 on Thursday. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.20. The stock has a 50 day moving average price of $16.21 and a 200 day moving average price of $13.82. Teva Pharmaceutical Industries Limited has a 52-week low of $7.42 and a 52-week high of $17.69.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). The company had revenue of $3.82 billion for the quarter, compared to analysts’ expectations of $3.70 billion. Teva Pharmaceutical Industries had a positive return on equity of 37.33% and a negative net margin of 2.88%. As a group, equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Bank of America boosted their price objective on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, May 30th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price on the stock in a research note on Friday, March 8th. Jefferies Financial Group upped their target price on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 20th. Finally, Barclays upped their target price on Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, June 5th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average price target of $17.00.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.